{
    "clinical_study": {
        "@rank": "131124", 
        "arm_group": [
            {
                "arm_group_label": "Tacrobell capsule 1mg", 
                "arm_group_type": "Experimental", 
                "description": "Tacrolimus 1mg / 1 capsule"
            }, 
            {
                "arm_group_label": "Prograf capsule 1mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Tacrolimus 1mg / 1 capsule"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate bioequivalence between tacrobell capsule 1mg and\n      prograf capsule 1mg."
        }, 
        "brief_title": "Bioequivalence Study of Tacrobell Capsule 1mg to Prograf Capsule 1mg", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Immunosuppression", 
        "detailed_description": {
            "textblock": "This will be an open label, randomized, single dose, 2-treatment, 2-period crossover study\n      in healthy volunteers.Study treatments will be administered under fasting conditions.\n\n      Blood samples for the analysis of tacrolimus in blood will be obtained as follows:\n      Predose(immediately prior to dosing), and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4,\n      6, 8, 12, 24, 48, 72 and 96 hours postdose."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed the informed consent from prior to screening test\n\n          -  Between 19 years and 55 years in healthy male subject\n\n          -  Have not any congenital or chronic disease and medical symptoms\n\n          -  Body mass index(BMI) of 18 to 30 and a total body weight \u2265 55kg\n\n          -  Appropriate subject for the study judging from investigator\n\n        Exclusion Criteria:\n\n          -  Evidence or history of clinically significant hepatic, renal, neurologic, immune\n             system, respiratory system, endocrine\n\n          -  Any condition possibly affecting drug absorption (e.g. gastrectomy)\n\n          -  Subject with hypersensitivity to tacrolimus or any excipient\n\n          -  Administration of cyclosporin or bosentan\n\n          -  Administration of potassium-sparing diuretics\n\n          -  Subject with hereditary diseases of galactose intolerance, Lapp lactase deficiency or\n             glucose-galactose malabsorption\n\n          -  SBP<90 mmHg or DBP<50 mmHg, SBP>150 mmHg or DBP>100 mmHg at least 3 minutes of rest\n\n          -  A positive HBsAg, HCV Ab, HIV Ab, RPR\n\n          -  AST, ALT > 1.5*upper limit of normal range at the screening test\n\n          -  Subject with a history of drug abuse or a positive reaction for drug abuse at the\n             screening test\n\n          -  Taking ETC medicine including oriental medicine within 14days before the first\n             hospitalization or taking OTC medicine, vitamin within 7days\n\n          -  Use of any drugs known to significantly induce or inhibit drug-metabolizing enzymes\n             within 30 days prior to initiation test\n\n          -  Participating in a bioequivalence study or other clinical study within 3 month\n             preceding the first hospitalization\n\n          -  Blood donation or more within 2 month or component blood donation within 1 month\n             prior to the first hospitalization\n\n          -  Continued to be drinking(alcohol> 21 units/week, 1 unit=10g of pure alcohol) or\n             during clinical trials can not be drunk\n\n          -  Severe heavy smoker(cigarette> 10 cigarettes/day) during  3 months or can not be\n             smoking during the clinical study\n\n          -  Continued to be taking caffeine or can not be taken caffeine\n\n          -  Continued to be taking grapefruit or can not be taken grapefruit\n\n          -  Not use of contraception during the clinical study\n\n          -  An impossible one who participates in the clinical trial by investigator's decision\n             including for reason of laboratory test result"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01910077", 
            "org_study_id": "Tacrobell_BE-1301"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tacrobell capsule 1mg", 
                "description": "1 capsule, oral, over the period I&II(crossover)", 
                "intervention_name": "Tacrobell capsule 1mg", 
                "intervention_type": "Drug", 
                "other_name": "Tacrobell capsule 1mg"
            }, 
            {
                "arm_group_label": "Prograf capsule 1mg", 
                "description": "1 capsule, oral, over the period I&II(crossover)", 
                "intervention_name": "Prograf capsule 1mg", 
                "intervention_type": "Drug", 
                "other_name": "Prograf capsule 1mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tacrolimus"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "tacrolimus", 
            "tacrobell capsule", 
            "prograf capsule", 
            "bioequivalence"
        ], 
        "lastchanged_date": "July 25, 2013", 
        "location": {
            "contact": {
                "email": "howardlee@snu.ac.kr", 
                "last_name": "Hyeong Ki Lee, MD, Ph.D", 
                "phone": "82-2-3668-7602"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul national university hospital"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study of Tacrobell Capsule 1mg Versus Prograf Capsule 1mg in Healthy Subjects", 
        "overall_contact": {
            "email": "howardlee@snu.ac.kr", 
            "last_name": "Hyeong Ki Lee, MD, Ph.D", 
            "phone": "82-2-3668-7602"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Hyeong Ki Lee, MD, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "AUClast: Area under the blood concentration-time profile from time zero to the time of the last quantifiable concentration", 
                "measure": "AUClast", 
                "safety_issue": "No", 
                "time_frame": "At pre-dose (immediately prior to dosing) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours postdese"
            }, 
            {
                "description": "Cmax: Maximum blood concentration", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "At pre-dose (immediately prior to dosing) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours postdese"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01910077"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "ACUinf: Area under the blood concentration-time profile from time zero extrapolated to infinite time", 
                "measure": "AUCinf", 
                "safety_issue": "No", 
                "time_frame": "At pre-dose (immediately prior to dosing) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours postdose"
            }, 
            {
                "description": "Tmax: Time for Cmax", 
                "measure": "Tmax", 
                "safety_issue": "No", 
                "time_frame": "At pre-dose (immediately prior to dosing) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours postdose"
            }, 
            {
                "description": "T1/2: Terminal elimination half-life", 
                "measure": "T1/2", 
                "safety_issue": "No", 
                "time_frame": "At pre-dose (immediately prior to dosing) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours postdose"
            }, 
            {
                "description": "CL/F: Apparent Clearance", 
                "measure": "CL/F", 
                "safety_issue": "No", 
                "time_frame": "At pre-dose (immediately prior to dosing) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours postdose"
            }
        ], 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}